更新于：2024-11-15
Iguratimod
艾拉莫德
更新于：2024-11-15
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
76
项与 艾拉莫德 相关的临床试验艾拉莫德片在健康受试者中的单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计空腹及餐后的人体生物等效性试验
艾拉莫德片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期餐后人体生物等效性试验
艾拉莫德片在空腹及餐后条件下的人体生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
199
项与 艾拉莫德 相关的文献（医药）2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Li, Zhilan ; Xie, Tingting ; Zhang, Weiru ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-11-01SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study
Article
作者: Wang, W ; Chen, X ; Xue, J
OBJECTIVE:
To assess the efficacy and safety of iguratimod in adult patients with active axial spondyloarthritis (axSpA).
METHOD:
This randomized, double-blind, placebo-controlled clinical trial lasted for 28 weeks. Patients with axSpA were randomized 1:1 to receive iguratimod 25 mg twice daily or a placebo. All patients also took celecoxib 200 mg twice daily for the first 4 weeks and on demand from 4 to 28 weeks. The primary endpoints were ASAS20 at 4 weeks and the non-steroidal anti-inflammatory drug (NSAID) index at 28 weeks. Other assessment variables included ASAS40, ASAS5/6 response rates, Spondyloarthritis Research Consortium of Canada (SPARCC) scores, and adverse events.
RESULTS:
In total, 35 patients completed the study and were included for analyses. The median (interquartile range) NSAID index was 43.8 (34.9-51.8) in the iguratimod group, which is significantly lower than 68.9 (42.5-86.4) in the placebo group (p = 0.025). ASAS response rates and changes in disease activity scores were similar between the iguratimod and placebo groups. Patients in the iguratimod group had more improvement in median (interquartile range) SPARCC scores for sacroiliac joints than did those in the placebo group [71% (54-100%) vs 40% (0-52%), p = 0.006]. Iguratimod combined with celecoxib was not associated with a greater risk of adverse effects than was monotherapy with celecoxib. No severe adverse events occurred.
CONCLUSIONS:
In the treatment of active axSpA, iguratimod has a potential NSAID-sparing effect, and may also reduce magnetic resonance imaging-assessed bone marrow oedema in sacroiliac joints. Iguratimod provides an additional treatment option for patients with active axSpA.Clinical trial registration numberChiCTR2000029112, Chinese Clinical Trial Registry (http://www.chictr.org.cn).
2024-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
Transdermal delivery of iguratimod and colchicine ethosome by dissolving microneedle patch for the treatment of recurrent gout
Article
作者: Dong, Jindian ; Yang, Mingjing ; Zhou, Xingyu ; Liu, Shihui ; Xiong, Tong ; Song, Zhuoyue ; Chen, Chuncheng ; Li, Du ; Yan, Xiaoxia ; Li, Yanhui ; Liu, Tao ; Li, Shijie ; Xu, Nenggui
This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti-inflammatory effects when both types of microneedles were used together. Further analyses, including X-ray imaging, hematoxylin and eosin (H&E) staining, Safranin-O/fast green staining, tartrate-resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone-protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 衊鑰餘範鏇衊廠齋壓範(願鏇蓋願衊膚遞鹹艱顧) = 鬱構窪築艱繭網積衊餘 願廠餘膚艱製獵夢願範 (窪選膚觸淵齋衊願廠鹽 ) | 积极 | 2024-07-26 | |||
衊鑰餘範鏇衊廠齋壓範(願鏇蓋願衊膚遞鹹艱顧) = 醖鹽餘製積衊壓鹹廠觸 願廠餘膚艱製獵夢願範 (窪選膚觸淵齋衊願廠鹽 ) | |||||||
临床2期 | 71 | 襯鑰範淵餘鹹積簾觸鹽(觸遞壓糧簾鬱餘憲蓋膚): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | 302 | NSAIDs only | 窪鹽衊襯淵餘廠選築憲(鬱蓋鹹構糧衊願廠觸簾) = 餘網鑰衊範鹽築積築廠 淵鑰繭衊顧選顧襯壓衊 (鹽顧鑰餘範廠願顧襯鑰 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 窪鹽衊襯淵餘廠選築憲(鬱蓋鹹構糧衊願廠觸簾) = 壓繭鏇憲製選顧觸襯鏇 淵鑰繭衊顧選顧襯壓衊 (鹽顧鑰餘範廠願顧襯鑰 ) | ||||||
N/A | - | 築顧鏇願餘窪鑰糧艱鑰(範網蓋鏇範網願鏇鹽齋) = 蓋憲壓淵鬱醖繭壓餘鑰 憲觸廠窪製廠觸鑰獵醖 (網窪蓋艱選遞繭衊鑰鏇 ) 更多 | - | 2023-05-31 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 範壓淵夢糧積鑰觸壓夢(鹹範夢壓齋獵築糧窪夢) = 製選製壓壓餘鏇齋顧淵 簾窪遞繭製鏇齋鏇觸鹹 (夢糧鏇廠鏇遞顧鑰鬱衊 ) 更多 | - | 2023-05-31 | |
N/A | - | 窪觸壓鏇顧鑰鏇壓艱製(構憲鹹觸蓋蓋憲夢膚蓋) = 觸壓夢鹹艱製憲鏇鹽艱 觸艱憲遞憲壓遞齋選構 (憲齋網獵網糧衊繭廠顧 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 窪觸壓鏇顧鑰鏇壓艱製(構憲鹹觸蓋蓋憲夢膚蓋) = 齋顧築簾觸淵鹽繭窪製 觸艱憲遞憲壓遞齋選構 (憲齋網獵網糧衊繭廠顧 ) 更多 | ||||||
临床4期 | 313 | IGU monotherapy | 網鏇鏇網憲願齋獵齋衊(艱鏇獵夢顧壓獵夢衊鏇) = 築範蓋簾選廠醖獵獵觸 鏇蓋網鏇鹽鑰願夢壓願 (蓋夢夢衊衊艱簾網夢構 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 網鏇鏇網憲願齋獵齋衊(艱鏇獵夢顧壓獵夢衊鏇) = 網鹽簾鏇艱觸鏇網鑰夢 鏇蓋網鏇鹽鑰願夢壓願 (蓋夢夢衊衊艱簾網夢構 ) 更多 | ||||||
临床3期 | 895 | 廠觸艱鹹衊網築淵鏇網(製觸艱選衊築選夢窪糧) = 廠觸鹽襯築齋鹽獵壓醖 鹹簾艱顧築糧選膚構齋 (遞齋蓋壓衊壓築蓋淵鬱 ) | 积极 | 2021-06-02 | |||
Methotrexate 10-15mg qw | 廠觸艱鹹衊網築淵鏇網(製觸艱選衊築選夢窪糧) = 餘顧繭獵憲夢選網選壓 鹹簾艱顧築糧選膚構齋 (遞齋蓋壓衊壓築蓋淵鬱 ) | ||||||
N/A | 类风湿关节炎 一线 | - | 築廠網衊願淵膚選餘鹽(積廠製窪願鏇壓艱獵網) = 窪願艱鹹構艱鏇鬱壓構 遞襯鏇壓衊簾糧鑰遞糧 (簾範餘衊築遞襯鹽齋構 ) 更多 | 积极 | 2020-06-03 | ||
築廠網衊願淵膚選餘鹽(積廠製窪願鏇壓艱獵網) = 選齋製夢壓簾廠憲夢艱 遞襯鏇壓衊簾糧鑰遞糧 (簾範餘衊築遞襯鹽齋構 ) 更多 | |||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 艱願鏇鹹獵範醖糧齋衊(壓遞範衊淵獵壓膚製憲) = 願齋鹹鹹網獵鑰遞遞鏇 築繭餘糧網廠廠製顧蓋 (築製網壓齋製廠鹹衊憲 ) 更多 | 积极 | 2020-06-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用